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prior to treatment initiation. Multinomial logistic regression
models were used to estimate the probability of treatment 
with olanzapine, quetiapine, or risperidone (reference group)
monotherapy based on patients’ demographic, clinical charac-
teristics and health care resource utilization during the three
months prior to treatment initiation. RESULTS: A total of 838
patients (mean age 38.9 [SD: 11.4] years) met inclusion criteria.
Patients were initiated on monotherapy with either olanzapine
(n = 393), risperidone (n = 262), or quetiapine (n = 183). Com-
pared to risperidone, patients aged 25–34, and 55–64 years were
more likely than other age groups to receive olanzapine. African-
American patients were less likely to initiate olanzapine or que-
tiapine. Women were more likely than men to receive quetiapine,
compared with risperidone. Patients whose ﬁrst bipolar episode
was depressive or who had used second generation antidepres-
sants during the three-month baseline period were less likely to
initiate olanzapine. Patients who used second generation antide-
pressants were more likely to receive quetiapine than risperidone.
Patients in the two counties with the largest population of
patients diagnosed with bipolar disorder were less likely to 
initiate quetiapine. CONCLUSIONS: Several variables, includ-
ing gender, race, type of ﬁrst bipolar episode, and county of res-
idence were associated with the choice of atypical antipsychotic
monotherapy used to treat bipolar disorder.
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OBJECTIVES: This study aims to evaluate the impact of Atten-
tion Deﬁcit Hyperactivity Disorder (ADHD) Narcolepsy Clini-
cal Prior Authorization program on prescription drug utilization
and costs. METHODS: Using pre-post with control group
approach, prescription records from April 2003 to June 2005
were obtained from pharmacy claims database in a pharmacy
beneﬁt management organization. The study group comprised of
eight clients enrolled in ADHD Narcolepsy program, while the
control group comprised of all other clients not enrolled in this
program. Number of prescriptions dispensed per month per
thousand eligible members, and per member per month (PMPM)
total, plan and member costs were analyzed and compared.
PMPM cost savings were calculated using the following formula:
Y¢ = Yst0*Rct - Yst1 where Yst0 and Yst1 represent actual pre and
post PMPM costs in the study group and Rct is the ratio of
PMPM post and pre costs in the control group. RESULTS: The
study group included 60,916 eligible lives from eight clients, and
the control group included 526,612 lives from 109 clients. From
the pre to post period, in the study group, the average number
of prescriptions per month per thousand eligible lives and the
average PMPM total costs decreased by 35% (from 7.38 to 4.82)
and 24% (from $0.68 to $0.51) respectively. In the control
group, however, the average number of prescriptions and the
average PMPM costs increased by 40% (from 5.18 to 7.25) and
68% (from $0.47 to $0.79). After comparing the trend in these
two groups, ADHD Narcolepsy Clinical Prior Authorization was
estimated to result in $0.63 PMPM and $460,525 annualized
cost savings for the eight clients as a whole. CONCLUSION:
ADHD Narcolepsy Clinical Prior Authorization program led to
decrease of prescription utilization and savings in PMPM costs
and was an effective strategy in controlling prescription drug 
utilization and costs.
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OBJECTIVES: This study evaluated the impact of Selective 
Serotonin Reputake Inhibitor (SSRI) Step Care program on 
prescription drug utilization and expenditures. METHODS:
Using pre-post with control group study approach, prescription
records from October 2003 to April 2005 were obtained from
pharmacy claims database in a pharmacy beneﬁt management
organization. The study group comprised of patients enrolled in
SSRI Step Care, while the control group comprised of those not
enrolled in this program. Number of prescriptions dispensed and
total costs per member per month (PMPM) for both targeted
brand drugs and shift-to-generic drugs were compared between
the study and control groups. RESULTS: The study group
included 62,451 eligible lives, and the control group included
341,971 lives. From the pre to post period, in the study group,
the average number of prescriptions per month per thousand eli-
gible lives and the average PMPM total costs decreased by
37.5% (from 26 to 16.26) and 31.3% (from $2.25 to $1.54) for
the target drugs, and increased by 48% (from 11.7 to 17.3) and
15.4% (from $0.79 to $0.91) for the shift-to-drugs respectively.
In the control group, however, the average number of prescrip-
tions and the average PMPM costs increased by 18.3% (from
21.18 to 17.31) and 13.4% (from $1.95 to $1.69) for the target
drugs, decreased by 8.6% (from 10.4 to 9.5) and 25% (from
$0.82 to $0.62) for the shift-to-drugs. SSRI Step Care was esti-
mated to result in $0.41 PMPM cost savings in the target drugs
but $0.31 PMPM cost increase in the shift-to-drugs, and a net
PMPM total cost savings of $0.10. CONCLUSIONS: SSRI Step
Care was found to shift prescription drug utilization from expen-
sive brand names to low cost generics. A medication manage-
ment program such as SSRI Step Care has been shown to lower
prescription drug expenditures.
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OBJECTIVES: To evaluate the likelihood of employment termi-
nation among patients with bipolar disorder (BPD) treated with
different classes of psychotropic medications. METHODS:
Patients with BPD (classiﬁed according to ICD-9-CM codes)
were identiﬁed from the Human Capital Management Services
Research Reference Database. Patients with continuous eligibil-
ity six months before and 12 months after their initial prescrip-
tion treatment for BPD were categorized into those using:
atypical antipsychotics only (ATYP); conventional antipsy-
chotics, mood stabilizers (including lithium, divalproex, lamot-
rigine, and carbamazepine), and speciﬁc anticonvulsants only
(OTHER); medications from both categories (BOTH); and no
study-speciﬁed psychotropic medications (NONE). The index
“prescription” date for the NONE group was deﬁned as six
months after the initial diagnosis. Both voluntary and involun-
tary terminations of employment were included. Regression
models controlled for possible confounding factors (age, gender,
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location, salary, race, marital status, full-time/part-time status,
prior comorbidity index, prior medical costs related to BPD,
prior other medical costs, index date, and medical services
related to BPD). Treatment groups were compared over a follow-
up period ranging from 12 to 24 months after the index pre-
scription date. RESULTS: Six hundred ninety-nine patients with
BPD were classiﬁed into the ATYP (n = 25), BOTH (n = 190),
NONE (n = 170), and OTHER (n = 314) treatment groups. The
ATYP group demonstrated the lowest rate of employment ter-
mination (1.5%; 95% CI -3.3%, 6.3%) followed by the BOTH
(5.8%; 95% CI 2.5%, 9.1%), NONE (8.9; 95% CI 4.7%,
13.2%), and OTHER (9.3%; 95% CI 6.1%, 12.5%) groups.
Differences between treatment groups were not signiﬁcant. The
numerical difference between ATYP and OTHER did not reach
signiﬁcance (p = 0.058). CONCLUSIONS: The ATYP group
demonstrated the lowest employment termination rate in the
follow-up period of 12 to 24 months after the index prescription
date. Further research is warranted to examine the inﬂuence of
speciﬁc patient variables and treatment regimens on employment
termination in patients with BPD.
PMH32
ANTIPSYCHOTIC THERAPY IN PATIENTS WITH BIPOLAR
DISORDER: EFFECTS ON TOTAL AND MENTAL HEALTH CARE
COSTS
Hassan M1, Madhavan SS2, Rajagopalan K1, Kalsekar ID3, Islam S2,
Makela EH2, Kavookjian J2, Miller LA2
1AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 2West
Virginia University, Morgantown, WV, USA, 3Butler University,
Indianapolis, IN, USA
OBJECTIVES: Compare total and mental health-related costs
among patients with bipolar disorder (BPD) initiated on queti-
apine versus other antipsychotics in a state Medicaid system.
Economic evaluations comparing quetiapine with other antipsy-
chotics are lacking in the published literature. METHODS:
Retrospective study using “de-identiﬁed” Medicaid claims data
of patients with BPD. Patients assigned to quetiapine (QTP),
olanzapine (OLZ), risperidone (RIS), or typical antipsychotic
groups based on ﬁrst prescription ﬁlled between January 1, 1999
and December 31, 2001. Total and mental health-related costs
(including study drug charges) from 12 months before until 12
months after treatment initiation were analyzed, controlling for
various confounders including patient demographics, comor-
bidities, and prior health care utilization. Total health care costs
included costs associated with medical and mental conditions.
Mental health-related costs were identiﬁed by claims associated
with a mental health disorder (ICD-9-CM codes
290.XX–316.XX) or CPT codes for psychiatric services
(90801–90899) and psychiatric medications. RESULTS: A total
of 825 patients with BPD were classiﬁed into OLZ (n = 283,
34.30%), RIS (n = 231, 28.00%), QTP (n = 106, 12.85%), and
typical antipsychotic (n = 205, 24.85%) cohorts. Mean (±SD)
total health care costs over the 12-month follow-up period were
US$15,866 ± US$23,164 (OLZ), US$17,539 ± US$17,570 (RIS),
US$13,227 ± US$18,862 (QTP), and US$17,570 ± US$23,842
(typical antipsychotics). Mean mental health-related costs over
the 12-month follow-up period were US$10,203 ± US$17203
(OLZ), US$9475 ± US$14202 (RIS), US$8064 ± US$7368
(QTP), and US$7,368 ± US$11,239 (typical antipsychotics).
Adjustment for confounders using multivariate analysis revealed
no signiﬁcant differences in total and mental health-related costs
between the QTP group and the other atypical antipsychotic
groups (OLZ, RIS). For the typical antipsychotic group, there
was greater total (28.4%) and mental health-related (8.7%) costs
compared with the QTP group. CONCLUSIONS: There were
no signiﬁcant differences in total and mental health-related costs
between atypical antipsychotic groups. However, patients with
BPD treated with QTP incurred lower total and mental 
health-related costs compared with those receiving typical
antipsychotics.
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OBJECTIVE: To describe the demographic and clinical charac-
teristics of Texas Medicaid enrollees prescribed AP therapy.
METHODS: This was a retrospective database analysis using
electronic medical records from 1997 to 2001 for adults receiv-
ing AP monotherapy who were continuously enrolled in Texas
Medicaid for at least 18 months. Patients were stratiﬁed accord-
ing to a hierarchy of mutually exclusive primary mental health
(PMH) categories for which AP therapy was presumed to be 
prescribed. RESULTS: Data were available for 19,430 patients.
The population was mainly female (65.7%), white (55.1%) and
older (mean age 60.3 years (SD: 21.9), with 47.6% ≥65 years).
PMH diagnoses were: schizophrenia 16.5%; bipolar disorder
15.5%; dementia 14.3%; psychosis 8.1%; non-psychotic disor-
der 14.5%; no mental health diagnosis 31.1%; with 32.1% of
patients having more than one mental health diagnosis. The per-
centages of index AP therapy were: ﬁrst-generation agent 29.3%;
clozapine 0.5%; olanzapine 21.6%; quetiapine 6.3%; risperi-
done 42.2%. This differed when stratiﬁed by age (c2 = 416.748,
df = 16, p < 0.001), gender (c2 = 76.901, df = 4, p < 0.001),
race/ethnicity (c2 = 160.710, df = 12, p < 0.001) and PMH diag-
nosis (c2 = 845.046, df = 20, p < 0.001). Risperidone use was
more common in those ≥65 years (48.3%), females (43.5%),
Hispanics (46.7%), and for dementia patients (50.1%). Olanza-
pine was primarily used in patients aged 45–54 years (33.6%);
males (31.6%); blacks (35.4%), and for schizophrenia (36.5%).
The mean daily dose of the second-generation antipsychotics
(SGAs) differed by age (p < 0.001) and treatment indication 
(p < 0.001). Regardless of the SGA, patients aged ≥65 years
received doses 43.4–51.2% lower than patients aged < 65 years.
Regardless of age, doses for schizophrenia were 26–46% higher
than for bipolar disorder and 60–70% higher than for dementia
patients. CONCLUSIONS: AP agents are prescribed for a
diverse range of indications with signiﬁcant differences in AP
dose according to treatment indication and patient age.
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OBJECTIVE: We compared factors associated with antidepres-
sant treatment selection for patients initiating on duloxetine
versus venlafaxine XR, bupropion, and SSRIs. We tested differ-
ences in subgroups with and without depression diagnoses.
METHODS:Claims from ﬁve US managed care health plans were
obtained for adult patients initiating on new prescriptions for
select antidepressants between August 31, 2004 to December 31,
2004. Diagnostic and treatment history were established through
prior claims (12 months before index medication date).
